Important caveat on # of events, but hard to look at this data and not be very excited. https://twitter.com/MaxNisen/status/1313876165938024448">https://twitter.com/MaxNisen/...
Baseline characteristics.

**I anticipate the definition of who is & #39;high risk& #39; is going to be a major issue for payers to decide who gets this therapy (depending on how EUA, if it goes through, is written)

The slide show with the Lilly data is here:
https://investor.lilly.com/static-files/a6dfdc90-3e16-4511-9a5d-f744b7568276">https://investor.lilly.com/static-fi...
the safety data look good, combined with what is known about safety of regeneron antibody so far.
Lilly has not opened up compassionate use it says in its conference call - they specify this is because of urgency of recruiting for clinical trials. https://abs.twimg.com/emoji/v2/... draggable="false" alt="😏" title="Grinsendes Gesicht" aria-label="Emoji: Grinsendes Gesicht">

They are stressing that drug should be available for EUA rather than rely on compassionate use.
Important caveat - they& #39;ve applied for EUA for the mono therapy in high risk patients based on AGE and Weight, not the combo therapy, which will be later in fall.

They have 1 million doses of mono available they say.
You can follow @walidgellad.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: